HomeBIOTECHNOLOGY

BIOTECHNOLOGY

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImmunoGen, Inc. is a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer.

Relation Therapeutics Teams Up with Mila in Coalition to Identify COVID-19 Therapeutic Candidates

Project RE will focus on finding therapies to tackle viral entry and replication and is co-led between Mila (Quebec AI Institute) and Relation Therapeutics, with the overall scientific direction by Mila founder Professor Yoshua Bengio.

National Science Foundation Awards Vitanova Biomedical a $225,000 Grant: Funds Allow for Research and Development on the Company’s Light-Activated Intracellular Acidosis

Vitanova Biomedical is developing a prostate-specific membrane antigen targeted drug, VNBp-1, formulated as a first line treatment for local stage prostate cancer.

Todos Medical Enters Into a $1.2 Million Contract for COVID-19 PCR Testing Equipment & Supplies with Texas-based Laboratory

The initial contract is for 8 months. Todos has also been granted a priority right to supply the lab with up to 75,000 COVID PCR tests per day in the event the laboratory sees significant additional testing demand.

‘Can We Cure Cancer with Artificial Intelligence?’ Predictive Oncology Announces DojoLIVE! Interview with Helomics CIO Mark Collins

The broadcast, titled ‘Can We Cure Cancer With Artificial Intelligence?’, is available for on-demand viewing on the DojoLIVE! website.

MEDISCA Names Reflex Medical as Exclusive Partner for SAMIX Mixer Repair

As the sole distributor of SAMIX mixing machines to the compounding market in the United States and Canada, MEDISCA, a global leader in the...

INTERCEPT Blood System Kit Shipments Surpass 7.5 Million Treatable Platelet and Plasma Doses Since Launch

William ‘Obi’ Greenman, Cerus’ president and chief executive officer explains, “This is a significant milestone for Cerus and highlights the scope our technology has had within the transfusion industry and on the millions of patients worldwide transfused with INTERCEPT treated platelet and plasma components. “We have a solid track record with the safety and efficacy of our INTERCEPT products, which now surpasses more than 7.5 million treatable doses.” 

Todos Medical Announces Partnership with Pathnova Laboratories

Under the terms of the agreements, PATHNOVA will be responsible for the further development and commercialization of the Todos Tests in Singapore, and Todos Medical will assist PATHNOVA in commercializing its nasopharyngeal cancer tests through its affiliates in the United States and Singapore.

Veracyte and MAVIDx Agreement in Place

Veracyte and MAVIDx agreement is intended to enable diagnostic testing and population screening for COVID-19 at an unprecedented scale – up to 40,000 samples per day performed on the easy-to-use nCounter instrument – through technology that attaches molecular barcodes to individual RNA molecules of the virus.